Alkermes (ALKS) Stock Forecast & Price Target

Compare

585 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$46.17

▲(64.53% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $46.17 with a high forecast of $58.00 and a low forecast of $37.00. The average price target represents a 64.53% change from the last price of $28.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","42":"$42","59":"$59","33.5":"$33.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.166666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.5,42,50.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.9,31.138461538461538,33.37692307692308,35.61538461538461,37.85384615384615,40.09230769230769,42.33076923076923,44.56923076923077,46.80769230769231,49.04615384615384,51.284615384615385,53.52307692307692,55.761538461538464,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.9,30.228205128205126,31.556410256410256,32.88461538461539,34.212820512820514,35.54102564102564,36.86923076923077,38.197435897435895,39.52564102564102,40.85384615384615,42.182051282051276,43.51025641025641,44.83846153846154,{"y":46.166666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.9,29.52307692307692,30.146153846153844,30.769230769230766,31.392307692307693,32.01538461538461,32.63846153846154,33.261538461538464,33.88461538461539,34.50769230769231,35.13076923076923,35.753846153846155,36.37692307692308,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$58.00

Average Price Target$46.17

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Benjamin Burnett

Wells Fargo

$37

Buy

31.86%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

12/08/25

Alkermes (ALKS) Gets a Hold from Bank of America Securities

David Amsellem

Piper Sandler

$45

Buy

60.37%

Upside

Reiterated

12/05/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Douglas Tsao

H.C. Wainwright

$46

Hold

63.93%

Upside

Reiterated

11/20/25

Cautious Optimism: Alkermes' Strategic Moves and Market Potential Amidst Investor Concerns

Leonid Timashev

RBC Capital

$47

Buy

67.50%

Upside

Reiterated

11/19/25

Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), Medtronic (MDT)

Joon Lee

Truist Financial

$50→$55

Buy

96.01%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

Akash Tewari

Jefferies

$58

Buy

106.70%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

60.37%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Ami Fadia

Needham

$44

Buy

56.81%

Upside

Reiterated

11/12/25

Alkermes' Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating

Joseph Thome

TD Cowen

$40

Buy

42.55%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

78.19%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

49.68%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)

Uy Ear

Mizuho Securities

$45

Hold

60.37%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securities

Marc Goodman

Leerink Partners

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Benjamin Burnett

Wells Fargo

$37

Buy

31.86%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Jason Gerberry

Bank of America Securities

Hold

―

Reiterated

12/08/25

Alkermes (ALKS) Gets a Hold from Bank of America Securities

David Amsellem

Piper Sandler

$45

Buy

60.37%

Upside

Reiterated

12/05/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Douglas Tsao

H.C. Wainwright

$46

Hold

63.93%

Upside

Reiterated

11/20/25

Cautious Optimism: Alkermes' Strategic Moves and Market Potential Amidst Investor Concerns

Leonid Timashev

RBC Capital

$47

Buy

67.50%

Upside

Reiterated

11/19/25

Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), Medtronic (MDT)

Joon Lee

Truist Financial

$50→$55

Buy

96.01%

Upside

Reiterated

11/17/25

Truist Financial Keeps Their Buy Rating on Alkermes (ALKS)

Akash Tewari

Jefferies

$58

Buy

106.70%

Upside

Reiterated

11/13/25

Jefferies Keeps Their Buy Rating on Alkermes (ALKS)

David Hoang

Deutsche Bank

$55→$45

Buy

60.37%

Upside

Reiterated

11/13/25

Alkermes (ALKS) Gets a Buy from Deutsche Bank

Ami Fadia

Needham

$44

Buy

56.81%

Upside

Reiterated

11/12/25

Alkermes' Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating

Joseph Thome

TD Cowen

$40

Buy

42.55%

Upside

Reiterated

11/12/25

Analysts Conflicted on These Healthcare Names: Alkermes (NASDAQ: ALKS), Xoma (NASDAQ: XOMA) and Novavax (NASDAQ: NVAX)

Umer Raffat

Evercore ISI

Buy

―

Reiterated

11/12/25

Alkermes' Strong Position and Misinterpreted Data: Justifying a Buy Rating

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$50

Buy

78.19%

Upside

Initiated

11/10/25

Alkermes (ALKS) Receives a New Rating from Roth MKM

Paul Matteis

Stifel Nicolaus

$36→$42

Buy

49.68%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Its Buy Rating for Alkermes (ALKS)

Uy Ear

Mizuho Securities

$45

Hold

60.37%

Upside

Reiterated

10/29/25

Alkermes (ALKS) Receives a Buy from Mizuho Securities

Marc Goodman

Leerink Partners

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

11/19 ratings generated profit

Average Return

+3.83%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of +3.83% per trade.

3 Months

xxx

Success Rate

14/19 ratings generated profit

Average Return

+5.61%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +5.61% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

12/19 ratings generated profit

Average Return

+16.18%

reiterated a buy rating last month

Copying Paul Matteis's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +16.18% per trade.

2 Years

xxx

Success Rate

16/23 ratings generated profit

Average Return

+8.16%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 69.57% of your transactions generating a profit, with an average return of +8.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 46.17.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.42 with a range of $0.29 to $0.50. The previous quarter’s EPS was $0.68. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $378.09M with a range of $357.00M to $400.84M. The previous quarter’s sales results were $394.19M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 46.17.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 64.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 46.17. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $37.00. The average price target represents 64.53% Increase from the current price of $28.06.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Detailed List of Analyst Forecasts